Dr. David
Founder and chairman
Pharmaceuticals
Levena Biopharma
China
Biography
He founded Concortis Biosystem in 2011 to develop site-specific ADC conjugation technology (C-Lock & K-Lock) and novel toxin payloads (Duostatin & Duomycin). In 2013, he sold Concortis Biosystem to Sorrento Therapeutics and is currently serving as company CTO. Prior to founding Concortis Biosystem, David was a director of chemistry and member of the senior management team at Ambrax, where he was instrumental in developing their ADC platform and portfolios. From 2000 to 2004, Dr Miao was a principal scientist at Enanta Therapeutics, where he was co-inventor of Paritaprevir, an HCV protease inhibitor and now part of the approved HCV combination therapy from Abbvie. Dr. Miao received his bachelor degree in chemistry from Nankai University in 1984 and Ph.D. degree in chemistry from Peking University in 1992. He also received post-doctorate training at Vanderbilt University from 1997 to 2000.
Research Interest
Business, Management, Finance, Pharmaceuticals, Immunology, Pharmacology
